Discontinued — last reported Q4 '20
Vertex Pharmaceuticals Revenue Recognized from Contract Liability remained flat by 0.0% to $51.70M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 21.4%, from $42.58M to $51.70M. Over 2 years (FY 2023 to FY 2025), Revenue Recognized from Contract Liability shows an upward trend with a 13.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
High levels indicate successful fulfillment of long-term contracts or subscription obligations.
The portion of revenue recognized during the period that was previously recorded as a contract liability. This demonstra...
Standardized as 'Revenue recognized from contract liability balance' under ASC 606.
is_tmusz_contract_liability_revenue_recognized| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $159.60M | $170.30M | $206.80M |
| YoY Change | — | +6.7% | +21.4% |